Therapeutic trial of lipid X in a canine model of septic shock.
Three groups of dogs were given lipid X (0, 1, or 10 mg/kg) every 8 h for for seven doses, starting simultaneously with the intraperitoneal placement of Escherichia coli-containing fibrin clots. All animals developed bacteremia, hypotension, and a pattern of decreased left ventricular ejection fraction characteristic of septic shock (P = .01). Survival rates and survival times were not significantly different between treatment groups (P > .2). In a similar experiment, higher doses of lipid X resulted in a significantly decreased survival time compared with concurrent controls (P = .04). Animals receiving lipid X did not differ from controls in serial determinations of temperature, hemodynamic measurements, or laboratory parameters (except serum total protein). Although lipid X has antiendotoxin effects, no benefit could be demonstrated in this antibiotic-treated, gram-negative bacillary-infected model of septic shock. These data do not support a therapeutic role for lipid X in the treatment of gram-negative sepsis.
Danner
R L
RL
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892.
Eichacker
P Q
PQ
Doerfler
M E
ME
Hoffman
W D
WD
Reilly
J M
JM
Wilson
J
J
MacVittie
T J
TJ
Stuetz
P
P
Parrillo
J E
JE
Natanson
C
C
D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000503:physiopathology; D006017:Glycolipids / Q000008:administration & dosage / Q000627:therapeutic use*; D006439:Hemodynamics; D007958:Leukocyte Count; D011897:Random Allocation; D012772:Shock, Septic / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D006017:Glycolipids; C044283:lipid X